Abstract

Chronic inflammation has emerged as a key player at different stages of cancer development. A prominent signaling pathway for acute and chronic inflammation is the activation of the caspase-1 inflammasomes. These are complexes that assemble on activation of certain nucleotide-binding domain, leucine-rich repeat containing proteins (NLRs), AIM2-like receptors (ALRs), or pyrin due to activation via PAMPs or DAMPs. Of these, five complexes—NLRP1, NLRP3, NLRC4, Pyrin, and AIM2 are of importance in the context of cancer for their activities in modulating immune responses, cell proliferation, and apoptosis. Inflammasomes have emerged as clinically relevant in multiple forms of cancer making them highly promising targets for cancer therapy. As lungs are a tissue niche that is prone to inflammation owing to its exposure to external substances, inflammasomes play a vital role in the development and pathogenesis of lung cancer. Therefore, manipulation of inflammasome by various immunomodulatory means could prove a full-proof strategy for the treatment of lung cancer. Here, in this review, we tried to explore the various strategies to target the inflammasomes for the treatment of lung cancer.

摘要

慢性炎症已成为癌症发展不同阶段的关键因素。急性和慢性炎症的一个重要信号通路是 caspase-1 炎症小体的激活。这些是在某些核苷酸结合域、富含亮氨酸重复序列的蛋白质 (NLR)、AIM2 样受体 (ALR) 或由于通过 PAMP 或 DAMP 激活而导致的pyrin 激活时组装的复合物。其中，NLRP1、NLRP3、NLRC4、Pyrin 和 AIM2 五种复合物在癌症环境中具有重要意义，因为它们具有调节免疫反应、细胞增殖和细胞凋亡的活性。炎症小体已在多种形式的癌症中具有临床相关性，使它们成为癌症治疗的非常有希望的靶点。由于肺是一个组织生态位，由于暴露于外部物质而容易发炎，炎症小体在肺癌的发生发展和发病机制中起着至关重要的作用。因此，通过各种免疫调节手段对炎性体进行操作可以证明是治疗肺癌的全能策略。在这里，在这篇综述中，我们试图探索靶向炎性体治疗肺癌的各种策略。